Category

Conditions

An update on the advancements in the treatment of agitation in Alzheimer’s disease

By | Dementia

Authors: Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch
Expert Opinion on Pharmacotherapy, April 2017

Neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD) are associated with significant negative outcomes for patients and their caregivers. Agitation, one of the most distressing NPS, lacks safe and effective long term interventions. Nonpharmacological interventions are s…

Read More

Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells.

By | Alzheimer's Disease

Authors: Rosaliana Libro, Francesca Diomede, Domenico Scionti, Adriano Piattelli, Gianpaolo Grassi, et al
International Journal of Molecular Sciences, 23 December 2016

Mesenchymal stem cells (MSCs) have emerged as a promising tool for the treatment of several neurodegenerative disorders, including Alzheimer’s disease (AD). The main neuropathological hallmarks of AD are senile plaques, composed of amyloid beta (Aβ), and neurofibrillary tangle…

Read More

The effects of Δ9-tetrahydrocannabinol on the dopamine system.

By | Behavioral Health, Substance-Related Disorders

Authors: Michael A. P. Bloomfield, Abhishekh H. Ashok, Nora D. Volkow, Oliver D. Howes
Nature, 17 November 2016

The effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, are a pressing concern for global mental health. Patterns of cannabis use are changing drastically owing to legalization, the availability of synthetic analogues (commonly termed spice)…

Read More

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

By | Immune System Diseases , Multiple Sclerosis

Authors: R. B. C. Kavia, D. De Ridder, C. S. Constantinescu, C. G. Stott, C. J. Fowler
Multiple Sclerosis Journal, November 2016

BACKGROUND: Bladder dysfunction is a common feature of multiple sclerosis (MS). OBJECTIVE: In this study we aimed to assess the efficacy, tolerability and safety of Sativex(®) (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS. METHODS: We un…

Read More

A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

By | Brain Cancer, Cancer

Authors: Susan Short, Christopher Twelves, Lucy Brazil, Catherine McBain, et al
Clinicaltrials.gov, 11 August 2016

An open-label phase to assess the frequency and severity of adverse events in recurrent glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part A). A randomisation phase to assess the safety of Sativex compared with placebo (Part B). Patient…

Read More

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.

By | Breast Cancer, Cancer

Authors: Clara Andradas, Sandra Blasco-Benito, Sonia Castillo-Lluva, Patricia Dillenburg-Pilla, et al
Oncotarget, 26 July 2016

The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the invo…

Read More

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

By | Anorexia, Behavioral Health, Brain Disorders, Clinical Endocannabinoid Deficiency, Digestive System Diseases, Headache Disorders, Immune System Diseases , Irritable Bowel Syndrome, Multiple Sclerosis, Nervous System Diseases, Parkinsonian Disorders, Stress Disorders - Post-Traumatic

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Read More

Cannabinoids and autoimmune diseases: A systematic review

By | Immune System Diseases 

Authors: Valeria Katchan, Paula David, Yehuda Shoenfeld
Autoimmunity Reviews, June 2016

Cannabinoids have shown to have a variety effects on body systems. Through CB1 and CB2 receptors, amongst other, they exert an effect by modulating neurotransmitter and cytokine release. Current research in the role of cannabinoids in the immune system shows that they possess…

Read More